Type-Specific Human Papillomavirus Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact by Ennaifer, Emna et al.
HAL Id: pasteur-02015508
https://hal-riip.archives-ouvertes.fr/pasteur-02015508
Submitted on 12 Feb 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Type-Specific Human Papillomavirus Distribution in
Invasive Squamous Cervical Carcinomas in Tunisia and
Vaccine Impact
Emna Ennaifer, Faten Salhi, Thalja Laassili, Emna Fehri, Nissaf Alaya, Ikram
Guizani, Samir Boubaker
To cite this version:
Emna Ennaifer, Faten Salhi, Thalja Laassili, Emna Fehri, Nissaf Alaya, et al.. Type-Specific Human
Papillomavirus Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact.
Asian Pacific Journal of Cancer Prevention, Asian Pacific Education Press Ltd., 2015, 16 (15), pp.6769-
6772. ￿10.7314/apjcp.2015.16.15.6769￿. ￿pasteur-02015508￿
Asian Pacific Journal of Cancer Prevention, Vol 16, 2015 6769
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.15.6769
Type-Specific HPV Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact
Asian Pac J Cancer Prev, 16 (15), 6769-6772
Introduction
HPV infection is the most common sexually transmitted 
infection all over the world and persistent infection with 
high risk HPV (HR-HPV) is the cause of cervical cancer 
(CC) (Walboomers M et al., 1999; Cogliano et al., 2005). 
The estimates CC burden in the world indicate an incidence 
of 529.000 cases/year and 275.000 deaths/year (Ferlay et 
al., 2010). Eighty percent of CC cases are killing women 
in under-resourced countries. Future projections have 
statute that the incidence will reach 1.000.000 cases/year 
in 2050 (Feraly et al., 2010). Among Tunisian women, this 
cancer now ranks third after breast and colorectal cancer 
(Ben Abdalah et al., 2009). However, since preventable, 
it is considered as a public health priority. In Tunisia, Pap 
smear screening programs have not been successful in 
preventing CC so the introduction of prophylactic HPV 
vaccination needs to be considered. Prophylactic HPV 
vaccines are designed to prevent HPV 16 and 18 infections 
and are considered efficient in reducing the burden of 
1HPV Research Unit, Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases, 3Department 
of Human and Experimental Pathology, Pasteur Institute of Tunis, 2National Observatory of Novel and Emergent Diseases, Tunis, 
Tunisia  *For correspondence: emna.jerbi@pasteur.rns.tn, emnaennaifer@yahoo.fr
Abstract
 Background: High risk human papillomaviruses (HPVs) are the leading cause of cervical cancer (CC) and 
Pap smear screening has not been successful in preventing CC in Tunisia. HPV vaccination that targets HPV16 
and 18 offers a new efficient prevention tool. Identification of HPV types in CC is thus essential to determine 
the impact of HPV vaccine implementation. The aim of this study is to provide specific data from Tunisia. 
Materials and Methods: A total of 89 histological confirmed paraffin embedded samples isolated from patients 
with CC diagnosed between 2001 and 2011 were collected from five medical centres from Northern and Southern 
Tunisia. HPV DNA was detected using a nested PCR (MY09/MY11-GP5+/GP6+) and genotyping was assessed 
using a reverse blot line hybridisation assay that enables the detection of 32 HPV types. Results: HPV DNA was 
detected in all samples. Twelve high risk types were detected; HPV16 and/or 18 were predominant, accounting 
together for 92.1% of all the CC cases (HPV16: 83.1%). Single infections accounted for 48.8% of the cases and 
were mostly linked to HPV 16 (32.6%) and less frequently to HPV 18 (2.4%). The other high risk HPV single 
infections were linked to HPV 35 (4.6%), 45 (4.6%), 58 (2.3%) and 59 (2.3%). Multiple infections with mixing 
of 2 to 4 genotypes predominately featrued HPV16 and/or 18 with HPV 35 and 45 (96.6 %) and less frequently 
with HPV 59, 40, 66, 73 and 58. There was no statistically significant variation in the relative distribution of 
HPV types with age. Conclusions: These results strongly indicate that prophylactic HPV vaccines can have a 
major impact in preventing CC in Tunisia 
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CC. Despite a constant rate distribution of HPV 16 and 
18 in CC all over the world (Kulkarni et al.,2011; Shen et 
Liu., 2013; Abdul Raub et al.,2014), regional variations 
have been documented (Clifford et al., 2003; Clifford et 
al., 2006). Thus, identification of HPV genotypes in CC 
is of great importance to determine the effectiveness of 
prophylactic vaccines implementation. The aim of the 
present study is therefore to determine using standardized 
protocols, HPV genotypes distribution in Tunisian 
specimens of squamous cell carcinoma (SCC) the most 
represented histotype of CC. 
Materials and Methods
Study population
The study was conducted at Pasteur Institute of Tunis 
(IPT), in the HPV unit Research of the  “Laboratory of 
Molecular Epidemiology and Experimental Pathology 
applied to infectious diseases” with straight collaboration 
of the Department of Human and Experimental Pathology. 
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Recruitment was performed in the period ranging from 
2001 to 2011. 89 archival selected paraffin embedded 
samples of diagnosed SCC were collected. The aim of 
the selection process was to avoid Bouin fixation that is 
unfortunately widely used and that causes DNA alterations 
(Longy et al., 1997; Benerini Gatta et al 2012). Biopsies 
and surgical specimens were assembled from 4 medical 
centers across the country: 68 samples from 3 Northern 
centers (24 from IPT, 30 from La Marsa hospital and 14 
from Nabeul hospital) and 21 samples from the hospital 
of Sfax located in the center of Tunisia. The diagnosis of 
primary SCC was confirmed by histopathology for all 
samples. 
Preparation of the paraffin samples
To ensure that HPV typing is performed onto DNA 
extracted from cancer tissue, a 4 µm thick section was 
stained with haematoxylin and eosin and evaluated by a 
pathologist of the Department of Human and Experimental 
Pathology (IPT). Four other sections of 10 μm thick each 
were further obtained from each paraffin block and kept 
in Eppendorf tubes for DNA extraction. To reduce the risk 
of cross-contamination, the blades were changed for each 
specimen and the microtome extensively washed with 
ethanol solutions. For each sample, a deparaffinization 
process eliminates the surrounding paraffin edges of the 
tissue section using a sterile crowbar. Then 3 washing 
steps in 65° Xylène and 4 washing steps with decreasing 
concentrations of ethanol were achieved at room 
temperature. A final heating of the samples was performed 
at 45°C to exclude paraffin remnants. 
DNA extraction, HPV DNA detection and typing
DNA extraction was performed using the QIA amp 
DNA Mini Kit (Qiagen) according to the manufacturer’s 
instructions. DNA quantification was assessed by 
spectrophotometry (A260/A280). HPV detection was 
performed with a nested PCR using MY09/MY11 
and GP5+/GP6+ biotinylated primers as described by 
Carvalho Nde O et al (Carvalho Nde et al., 2010) The 
first PCR was performed in a final reaction volume of 50 
μL, containing 10 to 25 ng of DNA, 10 μL of buffer [100 
mM Tris-HCl, 500 mM KCl], 50 µM of MgCl2, 2.5 µM 
of dNTPs, 10 µM of each primer and 2.5 U of Taq DNA 
polymerase. The second PCR was performed in a final 
volume of 50 μL, containing 1 μL of the first reaction, 10 
μL of buffer [100 mM Tris-HCl, 500 mM KCl], 50 µM 
of MgCl2, 2.5 µM of dNTPs, 10 µM of each primer and 
2.5 U of Taq DNA polymerase. 
Genotyping was performed by a Reverse Line Blot 
hybridization assay using the different biotinylated probes 
in a Miniblotter system (World Health organization, 2009; 
Eklund et al, 2010). The oligonucleotides were covalently 
joined to a Biodyne C membrane and activated with 
EDAC reagent (Sigma). The PCR products were denatured 
at 96°C, cooled on ice, and applied to each capillary of 
the Miniblotter. Hybridization was completed after 1 hour 
and the signal (peroxidase conjugate streptadivin Roche) 
was detected using a chemiluminescent autoradiography. 
This hybridization assay was performed for HLADQ and 
32 HPV genotypes: HPV 6 11, 16, 18, 26, 31, 33, 34, 35, 
39, 40, 42, 44, 45, 51, 52, 53, 54; 55, 56, 57, 58, 59a, 59b, 
66, 68, 69, 70, 73, 82, 83, 84. 
Statistical analysis
All statistical analyses were performed using 
SPSS 13.0. Descriptive analysis was performed and 
the proportion of different genotypes was calculated. 
Comparison of mean age according to HPV genotypes was 
achieved using T-test. Chi-square test was used to compare 
the distribution of different genotypes by age groups.
Results 
HPV detection
The study was conducted among 89 women aged from 
33 to 88 years (mean 56.47 ± 12.86 years). HPV DNA was 
detected in all samples using nested PCR. Thus, among all 
subjects of this study, the prevalence of HPV infection in 
SCC was 100 %. Sixteen HPV genotypes were detected 
including 12 high risk types. The most prevalent genotypes 
were HPV16 and HPV 18 detected in respectively 83.1% 
and 42.7% of samples. When both single and mixed 
infections were considered, HPV16 and/or HPV18 were 
detected in 92.1% of the SCC. Single infections accounted 
for 48.8% of the specimens and were mostly linked to 
HPV 16 (32.6% of single infections) and less frequently 
to HPV 18 (2.4%). The others HR-HPV single infections 
Figure 1. Proportional Distribution of Single and 
Mixed Infections with HPV16 and HPV 18 in this 
Series of Squamous Invasive Cervical Carcinoma 
Table 1. Proportional Distribution of HR-HPV Types 
that were Detected in this Series of Invasive Cervical 
Carcinoma
 Single Mixed 
 infections infections
HR-HPV type Total % number % number %
16 66 86.6 26 34.2 40 52.6
18 35 46 6 7.89 29 38.1
35 20 26.3 21 2.63 18 23.6
45 17 22.3 0 1.3 16 21
59 14 18.42 0 0 14 18.4
66 8 10.52 0 0 8 10.52
73 6 8.45 0 0 6 8.45
58 7 9.2 0 0 7 9.2
53 5 6.5 0 0 5 6.5
68 4 5.2 0 0 4 5.2
33 1 1 0 0 1 1
31 1 1 0 0 1 1
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were linked to HPV 35 (4.6%), 45 (4.6%), 58 (2.3%) 
and 59 (2.3%). Multiple infections were mixing 2 to 4 
HPV types and were predominately mixing HPV16 and/
or 18 with HPV 35 and 45 (96.6 %), and less frequently 
HPV16 and/or 18 with HPV 59, 40, 66, 73 and 58 (Figure 
1). Four low risk HPV types (HPV44, 40, 6 and 11) were 
detected in 22.4 % of SCC and were always mixed with 
HPV 16 and/or HPV18 and/or HPV35. The distribution 
of HR-HPV types is reported in table 1.
Statistical results
There was not any significant change in the relative 
distribution of the detected HPV types according to age 
using Chi-square test.
Discussion
The Tunisian CC incidence is similar to that seen in 
developed countries despite much lower screening (Cancer 
incidence in Five Continents, vol IX, 2007).According to 
the 2008 North cancer Tunisian registry of cancer, CC has 
moved from second to third women cancer after breast and 
colorectal cancer (Ben Abdallah et al., 2009). However, 
there is no statistics indicating a real decrease of its 
incidence and CC remains a national health problem and 
a national priority as it is a preventable cancer. Pap smear 
screening programs have not been efficient in preventing 
the disease (Njah et al, 1994; Hsairi et al., 2013; Lazzar 
et al., 2014) and vaccine implementation, considered as 
a valuable tool for CC control (Human Papillomavirus 
vaccines. WHO, 2009) is under investigation in Tunisia. 
Thus, collecting epidemiological data and information 
about HPV genotype distribution in CC is the keys to 
study the effectiveness of prophylactic strategies such 
HPV vaccination. HPV16 and 18 are the target of the two 
affordable HPV prophylactic vaccines and they have been 
established as the most common HPV types found in CC 
worldwide despite consistent regional variations (Munoz 
et al., 2004; De Sanjose et al., 2010; Sjoeborg., 2010). 
Efficacy of these vaccines in reducing CIN2/ CIN3 lesions 
associated with HPV 16 and 18 types has been estimated 
to 93%-100% (Harper et al., 2006; Villa et al., 2006). 
The first North African report describing HPV 
genotypes in CC was from Morocco (Chaouki et al., 
1998). The study published in 1998, shows that HPV 16 
and 18 are predominant (53.3% and 7.9 %). The second 
(Hammouda et al., 2005) reports a majority (95 %) of 
HPV 16 and 18 isolates from Algerian patients with CC. 
In our Tunisian series, we show that HPV 16 and/or 18 are 
present in 92.13 % of tested SCC. Two previous Tunisian 
studies showed similar findings. Missaoui et al report 
(Missaoui et al., 2010) shows using PCR technique and 
consensus GP5/GP6 primers, that HPV 16 is the most 
frequent detected genotype (47.6%) in the samples isolated 
from their patients. HPV 16 and 18 were also the most 
reported genotypes in a series of 146 cases collected in 
the Tunisian cancer Institute (KrennHrubec et al., 2011). 
Our results also show that multiple infections were seen 
in 51.7 % of cases and were mainly mixing HPV 16, 18, 
35 and 45 and less frequently HPV 59, 40, 66, 73 and 
58. Multiple infections have to be taken in consideration 
since the emergence of HPV genotype other than HPV16 
and HPV18 after vaccination could alter the effectiveness 
of vaccination. However, we could also consider that the 
immune response to HPV vaccine type can lead to a cross-
protection against the closely related species. Indeed, 
HPV 16 belongs to the A9 species which also includes 
types 31, 33, 52, 58, and 35. HPV 18 belongs to the A7 
species which also includes types 45, 59 and 39 and it 
has recently shown a cross protection for HPV35 and 45 
(Paavonen et al., 2009). 
At a technical level, while the usual HPV detection 
rate among formalin fixed and paraffin embedded samples 
is under 99 %, all the samples tested in our study were 
positive for HPV DNA. DNA fragmentation in formalin 
fixed paraffin embedded tissues are significantly more 
frequent compared to fresh tissues so DNA integrity 
usually decreases overtime in those samples and the 
probability to get false negatives increases ( Mc Sherry et 
al., 2007; Fattorini et al., 2009; Webersinke et al., 2013). 
This can be overcome in part by the use of the general 
primers GP5 and GP6 elongated at their 3’ ends with 
adjacent highly conserved sequence (De Roda et al., 1995; 
Lee, 2012) or the use of a nested PCR performed with 
MY09/MY11 and GP5+/GP6+ biotinylated primers as 
we did in our study (Carvalho et al., 2010). High levels of 
DNA concentration combined with these PCR conditions 
allow a detection of HPV DNA in 100 % of the samples. 
That was close to the findings of the Moroccan study 
that has been using a similar PCR protocol (Chaouki et 
al., 1998).
Our study shows that the prevalence of HPV 16 and/
or 18 is highly predominant in our Tunisian SCC series 
suggesting that the current prophylactic vaccines might be 
potentially effective in preventing the disease. If current 
screening policies need to be revised in Tunisia, these 
results indicate that HPV vaccination can have a major 
impact on CC preventive guidelines. Mixed infections are 
crucial when considering second generation vaccines with 
broader coverage of HPV types and the potential benefits 
of cross-protection with current vaccines. The prevalence 
of HPV 35 and 45 in our study is interesting to notice when 
considering the cross protection that has been described 
with HPV 35 and 45 (Paavonen et al., 2009). 
Cost-effectiveness analyses has been done in various 
parts in the world and has been conducted based on 
available data of HPV prevalence. The most important 
surveys have been assembled in a global meta-analysis. 
Besides differences in the PCR technologies used 
(Clifford et al., 2006), this analysis has provided relevant 
information for designing HPV vaccines and determining 
their impact in all world regions. Further documentation 
about HPV prevalence at a national level and its 
distribution according to age is needed to study the cost-
effectiveness of vaccine implementation in preadolescent 
girls and for the initial catch-up efforts in elder women (C 
Kitchener et al., 2014).
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